Subtype
Breast Carcinoma
CI-CAN-00000594Explore in graph →
872 active trials12 approved drugs113 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000594Explore in graph →
Clinical trials
2,392 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (364)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06955156 | Trilaciclib Combined With Anti-PD-1 Antibody and Chemotherapy in the Treatment of Locally Advanced TNBC | unknown | Phase 2 | 50 | QIAO LIOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06311357 | Percent Weight Change in the Medical Supplement Group of Early Breast Cancer | unknown | N/A | 40 | Department of Medical Services Ministry of Public Health of ThailandOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04660929 | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | unknown | Phase 1 | 48 | Carisma Therapeutics IncINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT04551495 | Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)(ROSALINE) | unknown | Phase 2 | 65 | Jules Bordet InstituteOTHER | 2 | Dec 4, 2024 | clinicaltrials |
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT06224387 | CTS2190 Phase I /II Clinical Study in Patients | unknown | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | Aug 23, 2024 | clinicaltrials |
| NCT05169853 | Programmed Death-Ligand1 Expression in Her-2 Positive and Triple Negative Breast Cancer | unknown | — | 80 | Ain Shams UniversityOTHER | 1 | Aug 20, 2024 | clinicaltrials |
| NCT05963464 | RADIOSO MILAN I (RADar Reflector localisatiOn-SCOUT for carcinOma Mammae, the MILAN IEO Experience I)(RADIOSO) | unknown | — | 300 | European Institute of OncologyOTHER | 1 | Aug 5, 2024 | clinicaltrials |
| NCT06479460 | Clinical Application of ctDNA Dynamic Monitoring in Neoadjuvant Therapy for HER2-positive Breast Cancer Patients | unknown | — | 50 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04197856 | Direct Information to At-risk Relatives(DIRECT) | unknown | N/A | 490 | Umeå UniversityOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT06355037 | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer | unknown | Phase 2 | 10 | Fudan UniversityOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT04432857 | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | unknown | Phase 1 | 63 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 2 | Jun 27, 2024 | clinicaltrials |
| NCT02977468 | Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer(Pembro/IORT) | unknown | Phase 1 | 15 | Eileen ConnollyOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT06439940 | Oncoliq: Early Breast Cancer Detection Based on Liquid Biopsies and microRNAs | unknown | — | 364 | Oncoliq US IncINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT06448169 | Observational Study on the Sensitivity of Neoadjuvant Immunotherapy in Early Triple-Negative Breast Cancer | unknown | — | 200 | Shandong UniversityOTHER | 0 | Jun 7, 2024 | clinicaltrials |
| NCT06441240 | Evaluation of Recurrence Risk Factors in Locally Advanced Breast Cancer Patients Underwent Neoadjuvant Chemotherapy.(NEORISK) | unknown | — | 933 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Jun 4, 2024 | clinicaltrials |
| NCT02993198 | A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging | unknown | Phase 2 | 134 | Northwestern UniversityOTHER | 1 | Jun 3, 2024 | clinicaltrials |
| NCT04418154 | Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients(NeoTENNIS) | unknown | Phase 2 | 70 | Fudan UniversityOTHER | 1 | May 21, 2024 | clinicaltrials |
| NCT05955105 | A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 200 | Innolake BiopharmINDUSTRY | 1 | May 21, 2024 | clinicaltrials |
| NCT06409221 | VISION: Triple Negative Breast Cancer Sample and Clinical Data Acquisition Study | unknown | — | 200 | ConcrINDUSTRY | 1 | May 10, 2024 | clinicaltrials |
| NCT05982626 | Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer | unknown | N/A | 10 | Huashan HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT06243432 | Estrogen Receptors and HER2 Levels' Expression in Luminal Metastatic Breast Cancer(CYCLHER) | unknown | — | 600 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | unknown | Phase 2 | 133 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Apr 15, 2024 | clinicaltrials |
| NCT03639948 | Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer(NeoPACT) | unknown | Phase 2 | 120 | University of Kansas Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05467111 | Cardioprotective Effect of Acute Exercise in Breast Cancer Patients(CardioProtEx) | unknown | N/A | 40 | Technical University of MadridOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06357338 | Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma | unknown | — | 70 | Marwa Mahmoud HassanOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06182306 | Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)(PEAR-MET) | unknown | — | 30 | Ourotech, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04914390 | A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer(NeoATCT) | unknown | Phase 2 | 32 | Sichuan Provincial People's HospitalOTHER | 1 | Jan 22, 2024 | clinicaltrials |
| NCT06210438 | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | unknown | Phase 2 | 24 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT05954442 | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype(BCTOP-T-M03) | unknown | Phase 3 | 203 | Fudan UniversityOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03812393 | Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast(FACT-2) | unknown | Phase 2 | 27 | West Cancer CenterOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT04197687 | TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery | unknown | Phase 2 | 480 | Academic and Community Cancer Research UnitedOTHER | 1 | Dec 18, 2023 | clinicaltrials |
| NCT06158217 | Effect of Ultrasound Combined With Microbubbles on Blood Perfusion in Invasive Breast Cancer | unknown | — | 30 | Beijing Friendship HospitalOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT04450732 | Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors | unknown | Phase 1 | 96 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 3 | Dec 5, 2023 | clinicaltrials |
| NCT06154109 | Comparative Efficacy of Xiaopi Granules and Decoction in Triple-negative Breast Cancer: a Randomized Controlled Trial | unknown | Phase 2 | 90 | Zhiyu WangOTHER | 0 | Dec 1, 2023 | clinicaltrials |
| NCT06152471 | Effect of Salovum™ and SPC-Flakes™ on Abemaciclib-induced Gastrointestinal Toxicity in Early Breast Cancer(ASF-BC) | unknown | Phase 3 | 100 | Henrik LindmanOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03906669 | A Window of Opportunity Study of Pre-operative Endocrine Therapy With and Without Prometrium in Postmenopausal Women With Early Stage Breast Hormone Receptor Positive (HR+) Human Epidermal Receptor 2 Negative (HER2-) Breast Cancer.(WinPro) | unknown | Phase 2 | 200 | St Vincent's HospitalOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT05912062 | Early On-treatment Transcriptional Profiling as Predictor of Response in Early-stage HER2-positive Breast Cancer(BiOnHER) | unknown | — | 80 | Institut Català d'OncologiaOTHER | 1 | Sep 29, 2023 | clinicaltrials |
| NCT05174832 | Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients | unknown | Phase 2 | 136 | Fudan UniversityOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT05985187 | Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer. | unknown | Phase 3 | 412 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT05932758 | Excisional Vacuum-Assisted Breast Biopsy | unknown | N/A | 300 | European Institute of OncologyOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT05953168 | T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients | unknown | Phase 2 | 69 | Fudan UniversityOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05945368 | A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC | unknown | Phase 2 | 78 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 14, 2023 | clinicaltrials |
Data updated 22 days agoSource updated May 2, 2025source: clinicaltrials